• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA MITRAL EASE PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES CARPENTIER-EDWARDS PERIMOUNT MAGNA MITRAL EASE PERICARDIAL BIOPROSTHESIS; REPLACEMENT HEART-VALVE Back to Search Results
Model Number 7300TFX
Device Problem Perivalvular Leak (1457)
Patient Problems Pleural Effusion (2010); Heart Failure/Congestive Heart Failure (4446)
Event Date 10/03/2023
Event Type  Injury  
Event Description
Edwards received notification that a valve model 7300tfx29mm implanted in the mitral position was explanted after an implant duration of thirty four (34) days due to paravalvular leak (pvl).Reportedly, during index procedure the native mitral leaflets were found to be very calcified and thickened, leading to combined stenosis and regurgitation.During index procedure, the anterior mitral leaflet was excised with conservation of sub valvular apparatus.As reported, the initial post-op echoes were satisfactory.However, the patient developed heart failure and pleural effusions with recurrence of the ventricular septal defect (vsd) caused and repaired during debridement of aortic valve at the index procedure, presenting with poor hemodynamics for a third redo cardiac surgery.During reintervention, the mitral bioprosthesis was explanted and a non-edwards mechanical valve was implanted in replacement.Vsd repair with a pericardial patch and aortic valve replacement (avr) were performed concomitantly.Unfortunately, at the end of procedure, the patient had relatively poor hemodynamics and unfortunately passed away on the same day after leaving the theatre to be transferred for further intensive care management.
 
Manufacturer Narrative
H10: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Manufacturer Narrative
H10: additional manufacturer narrative: the device history record (dhr) was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.The device was not returned for evaluation, therefore customer report of perivalvular leak could not be confirmed by product evaluation.Regurgitation is considered to be a perivalvular leak (pvl) if a turbulent eccentric jet originates between the bioprosthetic sewing ring and the annulus.Pvl can occur in the mitral and aortic position for similar reasons.In the early postoperative period, the highest incidence of pvl has been seen in patients developing infective endocarditis, which is most likely attributed to inadequate peri-operative antibiotic prophylaxis or nosocomial infection.Annular calcification is also a risk factor for the development of peri-operative pvl as the bioprosthesis may not seat properly after debridement.Technique related factors, such as incorrect valve sizing, have been shown to contribute to the development of pvl.Anatomical factors may create difficulty seating the bioprosthetic valve resulting in pvl.The anatomy of the annulus may induce mechanical stresses along the rigid bioprosthetic ring which can influence long-term valve performance and durability.A diseased or rigid annulus can potentially increase the mechanical stress on the prosthetic valve, leading to pvl.The instructions for use (ifu) have been reviewed and no inadequacies have been identified with regard to warnings, contraindications, and the directions/conditions for the successful use of the device.The reported type of event is included in the ifu.The most likely cause is procedural factors, including inadequate debridement of calcium before the valve was implanted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CARPENTIER-EDWARDS PERIMOUNT MAGNA MITRAL EASE PERICARDIAL BIOPROSTHESIS
Type of Device
REPLACEMENT HEART-VALVE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
one edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
one edwards way
mle fl2 office m2013
irvine, CA 92614
9492506615
MDR Report Key18383565
MDR Text Key331214273
Report Number2015691-2023-18726
Device Sequence Number1
Product Code DYE
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P860057
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 01/31/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number7300TFX
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 11/28/2023
Initial Date FDA Received12/22/2023
Supplement Dates Manufacturer Received01/26/2024
Supplement Dates FDA Received01/31/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured09/08/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Life Threatening; Hospitalization; Required Intervention;
Patient Age61 YR
Patient SexMale
-
-